Background: When pre-eclampsia (PE) occurs, it is a multi-organ condition with an unknown cause that is classified as a high-risk pregnancy marked by hypertension and proteinuria. Many antihypertensive medications are utilised, but they have drawbacks, whereas the use of labetalol to treat hypertension in women with pre-eclampsia has shown to be effective. Our findings may aid in underlining the importance of adequate treatment for pre-eclamptic patients who are in danger.

Objective: To evaluate the effectiveness of intravenous labetalol in the treatment of pre-eclampsic pregnant women who presented to a public service tertiary hospital.

Study Design: Descriptive study.

Place and Duration of Study: Department of Obstetrics and Gynecology, Shaikh Zaid Women Hospital, Larkana from 1^st June to 30^th November 2020.

Methodology: One hundred women with pre-eclampsia who had a singleton pregnancy on ultrasonography. Then intravenous labetalol 20mg, 40mg, 80mg, then 80mg every 15 minutes until goal blood pressure was obtained. Every 30 minutes, blood pressure was taken.

Results: The mean age was 31.25±5.30 years. There were 24% patients with pre-eclampsia achieved target blood pressure (150/100 mmHg) with one dose of intravenous labetalol, another 55% achieved target blood pressure with a second dose, and the remaining 21% achieved target blood pressure with a third dose.

Conclusion: Labetalol was found to be an effective treatment for women suffering from pre-eclampsia.

Keywords: Pre-eclampsia, Blood pressure, Intravenous labetalol